GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Inventories, Finished Goods

ANRO (Alto Neuroscience) Inventories, Finished Goods : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Inventories, Finished Goods?

Alto Neuroscience Inventories, Finished Goods Historical Data

The historical data trend for Alto Neuroscience's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Inventories, Finished Goods Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Inventories, Finished Goods
- - - -

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alto Neuroscience Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Alto Neuroscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Inventories, Finished Goods
Comparable Companies
CYCC STRO GUTS APLT AURX OKUR INO QNCX IKNA UNCY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Website
https://www.altoneuroscience.com
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.